-
November 20, 2024
Anti-abortion medical groups that were dealt a loss by the U.S. Supreme Court earlier this year have now dropped out of their lawsuit challenging federal approvals for mifepristone, leaving Missouri, Idaho and Kansas to carry on litigation over the abortion medication.
-
January 23, 2024
Republican attorneys general in Missouri, Idaho and Kansas moved to join the case in the U.S. Supreme Court challenging federal approvals for the abortion medication mifepristone, asking the justices to ensure the challenge isn't dismissed for lack of standing.
-
January 12, 2024
A Texas federal judge granted permission Friday for Missouri, Kansas and Idaho to join a lawsuit challenging federal approvals for the abortion medication mifepristone, ruling that the states have unique interests that aren't represented by others in the case.
-
December 18, 2023
The federal government asked a Texas court to reject a motion for intervention in a dispute over the abortion drug mifepristone, arguing that there was no point in adding Missouri, Idaho and Kansas to the suit when the original plaintiffs who sued lacked sufficient standing.
-
November 17, 2023
A Texas federal judge told the government to make its argument about why Missouri, Kansas and Idaho shouldn't intervene in a lawsuit over various rulings about the abortion drug mifepristone, saying that there's no need to wait for the U.S. Supreme Court to decide if it will review the case.
-
November 15, 2023
Missouri, Kansas and Idaho want a Texas federal judge to decide now whether they can join a lawsuit against the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services over the abortion drug mifepristone, instead of waiting to see if the U.S. Supreme Court weighs in on a Fifth Circuit ruling that would limit access to the drug.
-
November 06, 2023
Missouri, Kansas and Idaho have asked to join a lawsuit against the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services over the abortion drug mifepristone, with the states arguing they have special claims and rights to protect in the case.
-
April 12, 2023
A Texas federal court's recent decision upending certification of a pill used to terminate pregnancies will put pressure on the pharmacy benefit managers that act as intermediaries between drugmakers and insurers, attorneys say, heightening PBMs' potential legal exposure at the same time that states are seeking to ramp up regulations.
-
April 10, 2023
Chief executive officers and top legal counsel for pharmaceutical and biotech companies, including Pfizer, said a Texas federal judge's Friday order blocking the effective date of the U.S. Food and Drug Administration's decades-old approval of the abortion drug mifepristone fundamentally undermines the agency's authority and threatens industry.
-
April 07, 2023
A Texas federal judge Friday blocked the effective date of the U.S. Food and Drug Administration's decades-old approval of the abortion drug mifepristone and gave the Biden administration one week to appeal, drawing out a watershed ruling that could dramatically restrict abortion access in the U.S., where medication abortion has become the most common method to terminate pregnancies.